Sulfonate salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine
Flupirtine acid addition salts having the following formula (2), wherein R represents a substituted or unsubstituted C 1 -C 12 -alkyl or a substituted or unsubstituted C 6 -C 10 -aryl group, have been prepared.
1. A crystalline form of flupirtine mesylate characterized by data selected from the group consisting of: a powder XRD pattern with peaks at about 5.3, 10.6, 15.8, 19.5 and 22.1±0.2 degrees two theta, a powder XRD pattern as depicted in FIG. 3 ; and a combination thereof.
2. A crystalline form of flupirtine besylate characterized by data selected from the group consisting of: a powder XRD pattern with peaks at about 8.3, 12.4, 15.2, 21.4 and 28.7±0.2 degrees two theta, a powder XRD pattern as depicted in FIG. 6 ; and a combination thereof.
3. A pharmaceutical composition comprising the crystalline form of flupirtine mesylate according to claim 1 , and at least one pharmaceutically acceptable excipient.
4. A pharmaceutical composition comprising the crystalline form of flupirtine besylate according to claim 2 , and at least one pharmaceutically acceptable excipient.
5. A method of treating or preventing of acute or chronic pain, pain associated with degenerative or inflammatory joint disease, muscular tension, muscle spasm, muscle stiffness, neurodegenerative disorders, back pain, dementia, encephalopathy, diseases of the eye, myocardial ischemia or infarction, cerebral ischemia or infarction, shock, tinnitus and hepatitis, comprising administering a pharmaceutical composition according to claim 3 or claim 4 , to a patient in need thereof.